SAN DIEGO, Calif. – August 24, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast Track designation from the U.S.
Need help?
Contact usSAN DIEGO, Calif. – August 24, 2026 – ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that it has received Fast Track designation from the U.S.